Centogene receives Nasdaq delisting notice for non-compliance with market value requirement.

Centogene, a life sciences firm focusing on rare and neurodegenerative diseases, received a notice of delisting from Nasdaq due to non-compliance with the $15m Market Value of Publicly Held Shares requirement. The company plans to request a hearing to address the issue and prevent suspension or delisting. Despite the notice, Centogene will continue working with strategic partners to accelerate drug discovery, development, and commercialization.

February 28, 2024
3 Articles